TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00754052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (donepezil hydrochloride)
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept (donepezil hydrochloride)
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
Study: NCT03760016

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Aerobic Training
Description: Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
Study: NCT03090490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment discontinuation
Description: Withdrawal of antipsychotic medication to stabilized patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance treatment discontinuation
Description: Maintenance antipsychotic medication to stabilized patients
Study: NCT01374724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Ban
Description: Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Ban
Description: Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Use Ban
Description: Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Pamphlet
Description: A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Pamphlet
Description: A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Pamphlet
Description: The National Cancer Institute Pamphlet Clearing the Air was provided to subjects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention Intervention
Description: A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
Study: NCT02758548

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: Fingerprick and venous

Intervention type: DEVICE
Group type: OTHER
Intervention: POCT device
Description: Investigational device
Study: NCT00919334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Soft Contact (DISC) lens
Description: Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
Study: NCT01249014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed fluids
Description: IV fluids warmed by a Belmont fluid warmer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed fluids
Description: IV fluids warmed by a Belmont fluid warmer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid warmer and warming blanket
Description: Warm are blown into a Bair hugger warming blanket covering the patient

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belmont fluid warmer
Description: Belmont fluid warmer used to warm fluids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belmont fluid warmer
Description: Belmont fluid warmer used to warm fluids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair hugger warming blanket
Description: Bair hugger warming blanket laid on body
Study: NCT02988271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interview

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Participate in interview

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation Therapy
Description: Complete meditation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study: NCT04034836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scalp blocks with ropivacaine and intravenous parecoxib
Description: Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scalp blocks with ropivacaine and intravenous saline
Description: Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
Study: NCT03920748

Intervention type: OTHER
Intervention: Group D
Description: According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D

Intervention type: OTHER
Intervention: Group E
Description: According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
Study: NCT02400177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotion regulation training
Description: This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
Study: NCT01149837

Intervention type: DEVICE
Intervention: InnoLIA HTLV I/II Score line immunoassay
Description: This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
Study: NCT04359667

Intervention type: DRUG
Intervention: Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]
Description: 1 - 8 mg per kg of body weight once, maximal 800 mg per dose (can be repeated once more after 12 hours, per clinician's assessment)
Study: NCT01786655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neosaxitoxin in saline
Description: NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoSTX + bupivacaine 0.2%
Description: NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml
Description: Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
Study: NCT00685542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein
Description: Diacerein 50mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01254097

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Probiotic capsule, 2 capsules twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Probiotic capsule, 2 capsules twice daily
Study: NCT02474381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EPCs plus PTA
Description: Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single PTA
Description: Angioplasty of arteries below tibial plateau level only
Study: NCT00423722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
Study: NCT04382391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gammaCore® Sapphire (non-invasive vagus nerve stimulator)
Description: Administer gammaCore® Sapphire daily, prophylactically, for three treatments (morning, mid-day and night, one hour before bed), each treatment consisting of two 2-minute doses/stimulations, one on each side of the neck. This would be a total of 6 treatments (2 doses x 3 times per day) of stimulation.~For acute respiratory distress or shortness of breath (SOB), administer one treatment consisting of two 2-minute stimulations, on the neck. If respiratory distress or shortness of breath persists 20 minutes after the start of the first treatment, administer a second treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care therapies
Description: Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care therapies
Description: Will receive standard of care therapies for the treatment of CoViD-19 infection and symptoms
Study: NCT04029506

Intervention type: OTHER
Description: this is an obsevational study which needs no interventions
Study: NCT02515448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Study: NCT00414271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 mg/m2 IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
Study: NCT00207129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
Study: NCT03595943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic index, pulse-based diet
Description: Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Moderate glycemic index hospital diet
Description: Diet that is derived from a regular hospital menu for patients
Study: NCT00885508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J
Study: NCT04966208

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: xenogeneic collagen matrix
Description: xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: xenogeneic collagen matrix
Description: xenogeneic collagen matrix called mucoderm used for root coverage for treatment of gingival recession instead of harvesting from the patients connective tissue
Study: NCT04303182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard 3 port TEP
Description: 3 port TEP inguinal hernia repair with 10mm. port under the umbilicus and two 5mm. port in line under the 10mm. port

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LESS TEP
Description: TEP inguinal hernia repair with one vertical skin incision under the umbilicus
Study: NCT05042271

Intervention type: DRUG
Intervention: meropenem
Description: each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.

Intervention type: DRUG
Intervention: meropenem
Description: each patient received a 1 hour infusion of a single dose of 1 g of meropenem diluted in 100 ml of normal saline solution, at the same time as the start of the first TPE and meropenem PK studies were carried out after the administration of meropenem. Blood samples (3 ml) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 8 hours after the start of the meropenem administration.
Study: NCT04204330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioQvark cardiac monitor and software, single-lead ECG
Description: Registration certificate for the medical device No. РЗН 2019/8124 dated February 15, 2019.~Product form: phone case.~Way of applying:~1. Download the CardioQVARK mobile application; create a profile.~2. Fill out the questionnaire:~   * age;~  * date of birth;~  * sex;~  * weight;~  * height;~  * blood type;~  * eye color;~  * hair color;~  * occupation;~  * town;~  * alcohol consumption;~  * tobacco use;~  * overeating;~  * insufficient sleep;~  * hypertension;~  * type 2 diabetes;~  * pacemaker;~  * the 10th revision of the International Classification of Diseases (ICD-10) code;~  * medicines.~3. Place index fingers on sensors that are on the case's backside and record 1-lead ECG of up to 3 minutes duration.~Recorded parameters:~* time parameters of the ECG intervals (RR, P, PR, QRS, QT, QTc);~* abnormal rhythms;~  * heart rate variability;~ * additional function - blood pressure and blood sugar diary. All recorded and calculated parameters are passed to the server.
Study: NCT00282776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Management for Postpartum Depression
Description: Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
Study: NCT03688854

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: SCFA mixture
Description: Intracolonic administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA mixture
Description: Intracolonic administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SCFA mixture
Description: Intracolonic administration
Study: NCT03265704

Intervention type: OTHER
Intervention: AGA - Control group
Description: Data processing from Patient Medical Files

Intervention type: OTHER
Intervention: SGA - Control group
Description: Data processing from Patient Medical Files

Intervention type: OTHER
Intervention: AGA-PIH Study group
Description: Monitoring PIH-related changes in the newborn

Intervention type: OTHER
Intervention: SGA-PIH Study group
Description: Monitoring PIH-related changes in the newborn
Study: NCT04569578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Policy
Description: The intervention will include:~i. Formalized physical activity policies implemented in preschools including the following:~1. A minimum of 3 hours of total daily outdoor time scheduled both in the morning and in the afternoon~2. At least 10 minutes teacher-led active play per day~3. A minimum of 1 weekly outdoor excursion~4. Meet the children outdoors when they arrive at preschool and/or picked up by their parents~5. Only use screen tablets and computers for educational teaching purposes~6. Communicating to, and encouraging, the parents to actively transport their children to and from preschools~ii. A study website with an activity bank also serving as a platform for inter-professional education that preschool teachers can share and communicate about engaging activities and experience~iii. Weekly follow-up and feedback by web-based questionnaires
Study: NCT01874184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Take part in weekly group counseling sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Set goals for changing dietary habits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Attend group exercise activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03071497

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive analysis of Zinc protoporphyrin
Description: In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
Study: NCT00217711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: irinotecan hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: oxaliplatin
Study: NCT02988271

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive supportive care
Study: NCT04491695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion for 71.5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antiplatelet
Description: Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antiplatelet
Description: Aspirin, clopidogrel or other antiplatelet drugs. Loading dose will be considered if the patients is not on antiplatelet therapy.
Study: NCT06274424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Friends Program
Description: A group CBT intervention comprising ten weekly 60-minute sessions followed by two booster sessions.
Study: NCT00987142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX501
Description: Cultured chimeric skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Occlusive non adherent dressing
Description: Application of an occlusive non adherent dressing in the skin donor site
Study: NCT03318887

Intervention type: DRUG
Intervention: Sofosbuvir/daclatasvir with or without ribavirin
Description: Direct-acting antiviral treatment for hepatitis C virus infection
Study: NCT01644162

Intervention type: DEVICE
Group type: OTHER
Intervention: iVAPS ventilation
Description: 3 months of ventilation on iVAPS mode